Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TENET HEALTHCARE CORPORATION

(THC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Tenet Healthcare Corp : Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tenet Healthcare Corporation of Class Action Lawsuit and Upcoming Deadline - THC

11/04/2016 | 07:41pm EDT

NEW YORK, NY / ACCESSWIRE / November 4, 2016 / Pomerantz LLP announces that a class action lawsuit has been filed against Tenet Healthcare Corporation ("Tenet" or the "Company") (NYSE: THC) and certain of its officers. The class action, filed in United States District Court, Northern District of Texas, and docketed under 16-cv-02848, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Tenet securities between February 26, 2013 and September 30, 2016 inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act").

If you are a shareholder who purchased Tenet securities during the Class Period, you have until December 6, 2016 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.

[Click here to join this class action]

Tenet, together with its subsidiaries, primarily operates acute care hospitals and related healthcare facilities. The Company operates through three segments: Hospital Operations and Other, Ambulatory Care, and Conifer. As of December 31, 2015, the Company operated 86 hospitals, 20 short-stay surgical hospitals, approximately 475 outpatient centers, and 9 private hospitals and clinics, as well as 249 ambulatory surgery centers, 20 imaging centers, and 35 urgent care centers in the United Kingdom.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) certain of Tenet's hospitals had paid kickbacks for obstetric referrals; (ii) these kickbacks were in violation of federal law; (iii) these kickbacks subjected Tenet to the risk of heightened regulatory scrutiny, as well as substantial fines; and (iv) as a result of the foregoing, Tenet's public statements were materially false and misleading at all relevant times.

On August 1, 2016, post-market, Tenet announced that the Company had reached an agreement in principle with federal and state authorities pursuant to which the Company would pay nearly $514 million to settle allegations that four Tenet hospitals in Georgia and South Carolina paid kickbacks for obstetric referrals. Under the settlement, two Tenet subsidiaries would plead guilty to one count of conspiracy to violate federal kickback laws.

On this news, Tenet's share price fell $1.34, or 4.64%, to close at $27.57 on August 2, 2016.

On October 3, 2016, Tenet issued a press release and filed a Current Report on Form 8-K with the SEC, announcing that the Company had finalized the agreement in principle announced on August 1, 2016.

On this news, Tenet's share price fell $0.91, or 4.02%, to close at $21.75 on October 3, 2016.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP


ę Accesswire 2016
All news about TENET HEALTHCARE CORPORATION
11:48aTENET HEALTHCARE : UBS Downgrades Tenet Healthcare to Neutral Rating from Buy, Adjusts Pri..
MT
07:36aTENET HEALTHCARE : UBS Starts Tenet Healthcare at Neutral With $83 Price Target
MT
09/21TENET HEALTHCARE : to Report its Third Quarter 2021 Results on October 20
BU
09/20INSIDER SELL : Tenet Healthcare
MT
09/08TENET HEALTHCARE : Barclays Adjusts Tenet Healthcare's Price Target to $79 from $78, Keeps..
MT
09/03TENET HEALTHCARE CORP : Change in Directors or Principal Officers, Financial Statements an..
AQ
09/03TENET HEALTHCARE : Cigna Extend Network Access Deal
MT
09/02TENET HEALTHCARE : and Cigna Extend and Expand Network Access
BU
09/02Tenet Healthcare Corporation and Cigna Corporation Announce Extended and Expanded Their..
CI
08/17TENET HEALTHCARE : Insider Selling in Tenet Healthcare (THC) Shares Continues
MT
More news
Analyst Recommendations on TENET HEALTHCARE CORPORATION
More recommendations
Financials (USD)
Sales 2021 19 632 M - -
Net income 2021 657 M - -
Net Debt 2021 13 112 M - -
P/E ratio 2021 12,0x
Yield 2021 -
Capitalization 7 643 M 7 643 M -
EV / Sales 2021 1,06x
EV / Sales 2022 1,02x
Nbr of Employees 97 900
Free-Float 67,8%
Chart TENET HEALTHCARE CORPORATION
Duration : Period :
Tenet Healthcare Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TENET HEALTHCARE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 72,67 $
Average target price 82,56 $
Spread / Average Target 13,6%
EPS Revisions
Managers and Directors
Saumya Sutaria President, CEO, Chief Operating Officer & Director
Daniel J. Cancelmi Chief Financial Officer & Executive Vice President
Ronald A. Rittenmeyer Executive Chairman
Paola M. Arbour Chief Information Officer & Executive VP
Howard B. Hacker Chief Compliance Officer & Executive VP